Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (NASDAQ: APTX) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference, running from November 29 to December 2, 2021. The pre-recorded fireside chat will be accessible on their website starting November 22, 2021, at 10 a.m. ET, and will remain available for 30 days. Aptinyx focuses on developing therapies for brain and nervous system disorders, with ongoing clinical trials for conditions including chronic pain and cognitive impairment, utilizing a unique mechanism to enhance NMDA receptor function.
Aptinyx Inc. (Nasdaq: APTX) announced the completion of enrollment in its Phase 2b study of NYX-2925 for painful diabetic peripheral neuropathy, with results expected in early to mid Q2 2022. The company is on track for additional Phase 2 readouts in 2022 for fibromyalgia and cognitive impairment studies. Additionally, Aptinyx secured a $50 million growth capital facility from K2 HealthVentures. Despite a $21.2 million net loss for Q3 2021, down from $11.3 million in Q3 2020, the company expects its current cash reserves to sustain operations through 2023.
Aptinyx Inc. (NASDAQ: APTX) has completed enrollment in its Phase 2b study of NYX-2925, targeting painful diabetic peripheral neuropathy (DPN). The study will assess the efficacy and safety of NYX-2925, a novel oral NMDA receptor positive allosteric modulator, over a 12-week treatment. Results are anticipated in early to mid 2Q 2022. CEO Norbert Riedel emphasized the significance of this milestone amid challenges posed by the pandemic. Positive results could advance late-stage development and address a significant market need for effective DPN treatments.
Aptinyx Inc. (NASDAQ: APTX) will host a conference call on November 9, 2021, at 5:00 p.m. ET to discuss its third quarter 2021 financial results and recent developments. Interested parties can participate by dialing (844) 200 6205 (domestic) or (929) 526 1599 (international) with conference ID 322632. The call will also be available via live audio webcast on the company's website, with a replay accessible for 30 days post-event. Aptinyx focuses on developing innovative therapies for brain and nervous system disorders, with several candidates in clinical development.
Aptinyx Inc. (NASDAQ: APTX) has announced the appointment of Gilmore O’Neill, M.B., M.M.Sc., to its board of directors. O’Neill, currently the Chief Medical Officer at Sarepta Therapeutics, brings extensive expertise in neurological disorders, having previously worked at Biogen for over 15 years. His experience includes overseeing global marketing approvals for several key treatments. Aptinyx aims to innovate therapies targeting nervous system disorders, with O’Neill expected to contribute significantly to their growth and development initiatives.
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company, will have CEO Norbert Riedel participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:00 a.m. ET. A live webcast of the event will be available on the ‘Events and Presentations’ page on Aptinyx's website and archived for 30 days. Aptinyx specializes in developing therapies for brain and nervous system disorders, with three clinical candidates addressing chronic pain, PTSD, and cognitive impairment.
Aptinyx Inc. (Nasdaq: APTX) has announced a $50 million loan facility with K2 HealthVentures to support its clinical pipeline for treating brain disorders. The initial $15 million will be received immediately, with an option for an additional $10 million. The remaining $25 million is contingent upon achieving specific milestones. CEO Norbert Riedel emphasized that this financing will bolster their efforts as they advance towards three Phase 2 clinical study readouts and launch two additional studies.
Aptinyx Inc. (Nasdaq: APTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. Management will present virtually, starting at 7:00 AM ET on September 13. Interested parties can access the presentation on-demand through the conference portal and via a live webcast on Aptinyx’s website, which will also archive the event for 30 days. Aptinyx focuses on developing therapies for nervous system disorders and has three product candidates in clinical development.
Aptinyx Inc. (Nasdaq: APTX) reported its Q2 2021 financial results, revealing a net loss of $19.9 million, up from $12.6 million in Q2 2020. Cash and equivalents decreased to $129.2 million from $141.0 million. The company continues to advance its pipeline, with Phase 2b studies of NYX-2925 and NYX-458 on track for data readouts in 2022. A leadership transition is set, with Andy Kidd becoming CEO on January 1, 2022, succeeding Norbert Riedel, who will serve as executive chairperson.
